Skip to main content

ADVERTISEMENT

Poster

The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...
10/26/2023
This research examined real-world safety data for esketamine nasal spray (ESK) for the first 46 months after product approval, with a focus on adverse events (AEs) of interest (i.e., seda...
10/26/2023
In a retrospective analysis of 356 patients, abnormal CYP2D6 variants were significantly more prevalent in those with treatment-resistant depression than those with other types of depress...
10/26/2023
The prevalence of concomitant medication use in patients with schizophrenia has not been well established. This study aimed to bridge this gap by evaluating the annual prevalence of conco...
10/26/2023
Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.
10/26/2023
This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...
10/26/2023
Psychedelic therapy was offered to a couple 'cognitively stuck' on their dyadic journey through their grief work. On, their second mutual ketamine-experience they both entered the transp...
10/26/2023
We aim to investigate the elevated occurrence of Female Orgasmic Disorder (FOD) within our patient population, attributable to male sexual dysfunction (MSD) in their partners. Through a c...
10/26/2023
We present a study on the interplay between genetic variants and gene expression levels in depressed patients’ neurons and its association with antidepressant response. Neuronal expressio...
10/26/2023
Despite a relatively low prevalence, schizophrenia is one of the top 15 causes of disability worldwide and among the most expensive mental disorders to treat. Relapse, commonly associated...
10/26/2023